课题基金 / 基金详情

Tricuspid Valve Maladaptation: Its Stimuli, its Effect on Valve Function, and itsResponse to Therapy

Tricuspid Valve Maladaptation: Its Stimuli, its Effect on Valve Function, and itsResponse to Therapy
三尖瓣适应不良:其刺激、对瓣膜功能的影响及其对治疗的反应
批准号:
10852601
负责人:
MANUEL Karl RAUSCH
金额:
$19.77万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-06-20 至 2027-05-31

项目摘要

项目成果

MANUEL Karl RAUSCH的其他基金

相似基金

相关文献

中文摘要
翻译
摘要。三尖瓣返流严重影响了160多万美国人。在大多数病人中,
英文摘要
ABSTRACT. Tricuspid valve regurgitation severely impacts more than 1.6 million Americans. In most patients, tricuspid regurgitation is considered “functional” or due to valve-extrinsic factors. The valve itself is considered intact and thus viewed as an innocent bystander. Therefore, most treatment strategies focus on these valve- extrinsic factors and ignore the valve itself. Recently, we have shown that tricuspid regurgitation may not be so functional after all. In two separate sheep models of functional tricuspid regurgitation, we showed that the tricuspid valve leaflets fibrotically remodel, i.e., maladapt. Those leaflets grow in area and become both thicker and stiffer. Through computational studies, we further showed that maladaptation reduces leaflet compliance and their ability to successfully coapt, thus impeding valve function. These findings are of critical importance as tricuspid maladaptation may be a predictor for disease progression and patient outcomes. They may also explain the limited success of current treatment strategies. That is, they may explain why tricuspid valve repairs fail long- term in as many as 30% of patients. Finally, tricuspid maladaptation may also serve as a pharmacological target for future therapies. While others have shown that human tricuspid valve leaflets may remodel in disease by increasing their area, it has yet to be shown that they also thicken and stiffen. Thus, tricuspid maladaptation has not been fully confirmed in patients, a knowledge gap that stands between our novel discovery and improved diagnostic and therapeutic strategies for tricuspid regurgitation. The primary objective of this Administrative Supplement is to fill this knowledge gap. Specifically, we aim to demonstrate that human tricuspid valves also maladapt by thickening and stiffening. To this end, we will take an in-vitro approach using donated cadaver hearts. We will also explore a secondary objective and determine whether those valve properties are age and/or sex dependent. Thus, our specific aims are: 1) Demonstrate that human tricuspid valves maladapt in disease via thickening and stiffening; and 2) Test whether human tricuspid valve thickness and stiffness are age- and sex-dependent. The expected outcome of this work will be two-fold. First, at the conclusion of our work, we will know whether human tricuspid valves also maladapt. This is critically important to translating our research on sheep (as funded through the parent R01) to patients. Thereby, the combined work of this supplement and the parent grant will provide insight into the fundamental pathophysiology of heart valve disease. Additionally, we may thereby establish tricuspid maladaptation as a novel therapeutic target in patients. Second, we will have tested whether tricuspid valve thickness and stiffness are sex- and age-dependent. This is highly important to our understanding of basic valvular physiology/pathophysiology and will also likely inform differential treatment strategies dependent on patient sex and age. Overall, our effort will shed new light on a deadly disease and clearly leverages our parent grant with the help of the CAROL Act.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Valvular complex and tissue remodelling in ovine functional tricuspid regurgitation.
羊功能性三尖瓣反流的瓣膜复合体和组织重塑。
DOI: 10.1093/ejcts/ezad115
发表时间: 2023
期刊: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
影响因子: --
作者: [Iwasieczko,Artur, Gaddam,Manikantam, Gaweda,Boguslaw, Goodyke,Austin, Mathur,Mrudang, Lin,Chien-Yu, Zagorski,Joseph, Solarewicz,Monica, Cohle,Stephen, Rausch,Manuel, Timek,TomaszA]
通讯作者: Timek,TomaszA
Tricuspid Valve Maladaptation: Its Stimuli, its Effect on Valve Function, and its Response to Therapy
  • 批准号:
    10650421
  • 项目类别:
  • 资助金额:
    $70.03万
  • 财政年份:
    2022
  • 负责人:
    MANUEL Karl RAUSCH
  • 依托单位:
Tricuspid Valve Maladaptation: Its Stimuli, its Effect on Valve Function, and its Response to Therapy
  • 批准号:
    10504140
  • 项目类别:
  • 资助金额:
    $68.69万
  • 财政年份:
    2022
  • 负责人:
    MANUEL Karl RAUSCH
  • 依托单位:
Human-Specific Prediction, Training, and Visualization Tools for the Tricuspid Valve from Existing Data
  • 批准号:
    10360830
  • 项目类别:
  • 资助金额:
    $11.12万
  • 财政年份:
    2021
  • 负责人:
    MANUEL Karl RAUSCH
  • 依托单位:
Human-Specific Prediction, Training, and Visualization Tools for the Tricuspid Valve from Existing Data
  • 批准号:
    10533351
  • 项目类别:
  • 资助金额:
    $11.11万
  • 财政年份:
    2021
  • 负责人:
    MANUEL Karl RAUSCH
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: